文献速递中毒与环境急症消化、代谢与肾脏急症

州医疗补助丁丙诺啡事先授权要求的主题分析

Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.
PubMed 文献 · JAMA Netw Open · 2023-06-01
一句话结论多数州医疗补助计划仍对至少一种丁丙诺啡剂型要求事先授权,部分州设置尿药筛查、剂量上限等障碍,与现有证据冲突。

这项定性研究对2020年11月至2021年3月间美国50个州医疗补助网站上的丁丙诺啡事先授权表格进行主题分析,评估提示用药障碍的特征。多数州对至少一种丁丙诺啡剂型要求事先授权,但多数州对丁丙诺啡-纳洛酮不要求事先授权。识别出四类覆盖要求主题:限制性监测、行为健康治疗建议或强制、干扰或限制医疗决策、患者教育。11个州(22%)要求尿药筛查,18个州(36%)规定剂量上限,其中11个州(22%)对日剂量高于16 mg要求额外步骤。作者认为这些要求与现有证据冲突,可能负面影响各州应对阿片类药物过量危机的努力。

要点

  • 多数州医疗补助计划对至少一种丁丙诺啡剂型要求事先授权,但多数州对丁丙诺啡-纳洛酮不要求事先授权。
  • 11个州(22%)要求尿药筛查,6个州(12%)要求随机尿药筛查,4个州(8%)要求数药片。
  • 18个州(36%)规定剂量上限,其中11个州(22%)对日剂量高于16 mg要求额外步骤。
  • 14个州(28%)建议行为健康治疗,7个州(14%)要求治疗、咨询或参加小组会议。
  • 作者认为州医疗补助对丁丙诺啡的事先授权要求与现有证据冲突,可能负面影响应对阿片类药物过量危机。

适用人群与场景

  • 美国50个州的医疗补助计划中丁丙诺啡事先授权表格所覆盖的丁丙诺啡处方人群。

研究设计与关键结果

  • 设计:定性研究,对2020年11月至2021年3月间美国50个州医疗补助网站上的丁丙诺啡事先授权表格进行主题分析。
  • 多数州医疗补助计划对至少一种丁丙诺啡剂型要求事先授权,但多数州对丁丙诺啡-纳洛酮不要求事先授权。
  • 识别出四类覆盖要求主题:限制性监测(如要求尿药筛查、随机药物筛查、数药片)、行为健康治疗建议或强制(如强制咨询或参加12步会议)、干扰或限制医疗决策(如最大日剂量16 mg、日剂量高于16 mg需额外步骤)、患者教育(如关于不良反应和与其他药物相互作用的信息)。
  • 11个州(22%)要求尿药筛查,6个州(12%)要求随机尿药筛查,4个州(8%)要求数药片。
  • 14个州(28%)的表格建议治疗,7个州(14%)要求治疗、咨询或参加小组会议。
  • 18个州(36%)规定剂量上限;其中11个州(22%)对日剂量高于16 mg要求额外步骤。

证据类型、等级与局限

  • 证据类型:定性研究(对州医疗补助事先授权表格的主题分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为州医疗补助计划对阿片类药物使用障碍的丁丙诺啡事先授权要求与现有证据冲突,可能负面影响各州应对阿片类药物过量危机的努力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Prior authorization (PA) requirements for buprenorphine are associated with lower provision of the medication for the treatment of opioid use disorder (OUD). While Medicare plans have eliminated PA requirements for buprenorphine, many Medicaid plans continue to require them.

OBJECTIVE: To describe and classify buprenorphine coverage requirements based on thematic analysis of state Medicaid PA forms.

DESIGN, SETTING, AND PARTICIPANTS: This qualitative study used a thematic analysis of 50 states' Medicaid PA forms for buprenorphine between November 2020 and March 2021. Forms were obtained from the jurisdiction's Medicaid websites and assessed for features suggesting barriers to buprenorphine access. A coding tool was developed based on a review of a sample of forms, including fields for behavioral health treatment recommendations or mandates, drug screening requirements, and dosage limitations.

MAIN OUTCOMES AND MEASURES: Outcomes included PA requirements for different buprenorphine formulations. Additionally, PA forms were evaluated for various criteria such as behavioral health, drug screenings, dose-related recommendations or mandates or patient education.

RESULTS: Among the total of 50 US states in the analysis, most states' Medicaid plans required PA for at least 1 formulation of buprenorphine. However, the majority did not require a PA for buprenorphine-naloxone. Four key themes of coverage requirements were identified: restrictive surveillance (eg, requirements for urine drug screenings, random drug screenings, pill counts), behavioral health treatment recommendations or mandates (eg, mandatory counseling or 12-step meeting attendance), interfering with or restricting medical decision-making (eg, maximum daily dosages of 16 mg, requiring additional steps for dosages higher than 16 mg), and patient education (eg, information about adverse effects and interactions with other medications). Eleven states (22%) required urine drug screenings, 6 states (12%) required random urine drug screenings, and 4 states (8%) required pill counts. Fourteen states' forms (28%) recommended therapy, and 7 (14%) required therapy, counseling, or participation in group sessions. Eighteen states (36%) specified dosage maximums; among them, 11 (22%) required additional steps for a daily dosage higher than 16 mg.

CONCLUSION: In this qualitative study of state Medicaid PA requirements for buprenorphine, themes were identified that included patient surveillance with drug screenings and pill counts, behavioral health treatment recommendations or mandates, patient education, and dosing guidance. These results suggest that state Medicaid plans' buprenorphine PA requirements for OUD are in conflict with existing evidence and may negatively affect states' efforts to address the opioid overdose crisis.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Nguemeni Tiako MJ, Dolan A, Abrams M, et al. Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements. JAMA Netw Open. 2023. PMID: 37318805. doi:10.1001/jamanetworkopen.2023.18487

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。